COVID-19 Poses Higher Risk of Venous Thromboembolism than Influenza - EMJ

COVID-19 Poses Higher Risk of Venous Thromboembolism than Influenza

1 Mins
Hematology

RETROSPECTIVE analysis of data of 93,906 patients hospitalised with either COVID-19 or influenza has shown that the risk of infection-associated venous thromboembolism (VTE) was greater for patients with COVID-19 compared with patients with influenza, irrespective of COVID-19 vaccine availability. 

Leady study author Vincent Lo Re III, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, and colleagues analysed data from 41,443 patients hospitalised with COVID-19 before vaccine availability (between April and November 2020); 44,194 patients hospitalised with COVID-19 between December 2020 and May 2021, whilst vaccines were available; and 8,269 patients hospitalised with influenza between October 2018 and April 2019. The study aim was to evaluate the 90-day risk of VTE (deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (ischaemic stroke or myocardial infarction) between these groups. 

The researchers found that the 90-day absolute risk for VTE was higher in both the pre– and post– vaccine availability COVID-19 groups than in the influenza group. The absolute risk for the post-vaccine availability COVID-19 group was 10.9% (95% confidence interval [CI]: 10.6–11.1); 9.5% (95% CI: 9.2–9.7%) in the pre-vaccine availability COVID-19 group; and 5.3% (95% CI: 4.9–5.8) in the influenza group.

The absolute risk difference between the post-vaccine availability COVID-19 and influenza groups and the pre-vaccine availability COVID-19 and influenza groups was 5.5% (95% CI: 5.0–6.1) and 4.1% (95% CI: 3.6–4.7), respectively. The adjusted hazard ratio between the influenza and post-vaccine COVID-19 and the influenza and pre-vaccine availability COVID-19 groups was 1.89 (95% CI: 1.68–2.12) and 1.6 (95% CI: 1.43–1.79), respectively, further highlighting the elevated prothrombotic risk associated with COVID-19. 

No difference in the 90-day absolute risk for arterial thromboembolism was identified between either the pre-vaccine availability COVID-19 or the post-vaccine availability COVID-19 and influenza cohorts. 

Ro Le III and colleagues postulated several explanations for these differences in VTE risk, including “heightened awareness of thrombosis with COVID-19” or “increased abundance of anti-phospholipid antibodies and enhanced platelet activity” secondary to the effect of severe acute respiratory syndrome coronavirus 2 on endothelial cells. 

Whilst data on thrombotic event severity were unavailable, the findings from this research highlight the increased pro-thrombotic effect of COVID-19 compared with influenza, reiterating the importance of VTE prophylaxis in hospitalised patients. 

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given